Cancer Immunotherapy

Triple Therapy Successful for Some Metastatic RCC

Published in Cancer Weekly, May 17th, 1999

Triple combination therapy works in approximately 20 percent of metastatic renal cell carcinoma (RCC) patients.

D. Samland and colleagues from the University Magdeburg, Germany, evaluated the long-term clinical effects of a combination therapy with recombinant interleukin-2 (rIL-2), recombinant interferon-alpha(2) (rIFN-alpha(2)) and 5-fluorouracil (5-FU) in patients with advanced metastatic renal cell carcinoma (RCC) seen at a single institution ("Results of Immunochemotherapy with Interleukin-2, Interferon-Alpha(2) and 9-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer," European Urology, March 1999;35(3):204-209).

"From August 1992...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry